To Continue Expansions in Capacity, Geography and Portfolio
Samsung Biologics shared its 2023 business plans and vision at the 41st Annual J.P. Morgan Healthcare Conference, which took place between Jan. 9-12 in San Francisco, California, USA. During the main track presentation on Jan. 12, John Rim, CEO and president of Samsung Biologics, said the company will build on the strong growth momentum in 2022 with continued investments to further solidify its global position.
Based on its three-dimensional growth strategy, Samsung Biologics will continue expansions in capacity, geography and portfolio. While Plant 4 is due for full completion in mid-2023, the company has already acquired the land for Bio Campus II, which will host Plants 5 through 8. With active investments in future modalities via the Samsung Life Science Fund, Samsung Biologics will continue to pursue M&As to further boost competitiveness in 2023, and as part of global expansion, the company will operate a new regional office in New Jersey to work in proximity to clients and continue to evaluate expansion to other locations.
Samsung Biologics also continues to engage in environment-conscious practices and global initiatives to mitigate climate change risks. Reflecting the company’s net-zero efforts, Samsung Biologics was awarded the Terra Carta Seal from the Sustainable Markets Initiative.
“The strategies outlined today will not only drive growth this year but also build sustainable foundations for the long term,” said Rim. “We will continue to grow, ultimately to provide maximum satisfaction to our clients and to our investors.”